Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Tax Provisions (2017 - 2026)

Corcept Therapeutics (CORT) has disclosed Tax Provisions for 10 consecutive years, with -$13.0 million as the latest value for Q1 2026.

  • For Q1 2026, Tax Provisions fell 19.27% year-over-year to -$13.0 million; the TTM value through Mar 2026 reached -$35.2 million, down 1790.74%, while the annual FY2025 figure was -$33.2 million, 263.62% down from the prior year.
  • Tax Provisions hit -$13.0 million in Q1 2026 for Corcept Therapeutics, up from -$14.4 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $7.7 million in Q4 2022 and bottomed at -$14.4 million in Q4 2025.
  • Average Tax Provisions over 5 years is $427176.5, with a median of $4.1 million recorded in 2022.
  • Year-over-year, Tax Provisions surged 411.72% in 2023 and then tumbled 1314.36% in 2025.
  • Corcept Therapeutics' Tax Provisions stood at $7.7 million in 2022, then dropped by 28.92% to $5.5 million in 2023, then plummeted by 78.29% to $1.2 million in 2024, then crashed by 1314.36% to -$14.4 million in 2025, then increased by 9.58% to -$13.0 million in 2026.
  • According to Business Quant data, Tax Provisions over the past three periods came in at -$13.0 million, -$14.4 million, and -$4.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.